Sucampo Pharmaceuticals (SCMP) PT Raised to $19 at Maxim Group

November 15, 2016 7:33 AM

Maxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found